文献速递脑血管病

普伐他汀对颈动脉内膜中层复合体厚度的长期影响:J-STARS回声研究

Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke).
PubMed 文献 · Stroke · 2017-11-30

本研究为J-STARS试验的子研究,纳入非心源性缺血性卒中日本患者,随机接受普伐他汀10mg/日或不接受他汀,主要终点为5年观察期内颈总动脉IMT变化。结果显示普伐他汀组IMT年变化显著低于对照组(0.021±0.116 vs 0.040±0.118 mm,P=0.010),提示常规日本剂量普伐他汀可减缓颈动脉IMT进展。

要点

  • 普伐他汀10mg/日可显著减缓非心源性缺血性卒中患者5年颈总动脉IMT进展。
  • 普伐他汀组与对照组IMT年变化分别为0.021±0.116 mm和0.040±0.118 mm(P=0.010)。
  • 基线IMT两组均为0.887 mm,组间无显著差异(P=0.99)。

核心结论

  • 常规日本剂量普伐他汀(10mg/日)显著减缓非心源性缺血性卒中患者5年颈动脉IMT进展。

研究设计与样本

  • J-STARS试验子研究,多中心、随机、开放标签、平行组设计。
  • 纳入864例注册患者,排除71例无基线超声者,普伐他汀组388例,对照组405例。
  • 普伐他汀组接受10mg/日(日本常规剂量),对照组不接受任何他汀。
  • 主要终点为5年观察期内颈总动脉IMT变化,采用混合效应模型重复测量比较。

主要发现

  • 基线IMT均值±SD:普伐他汀组0.887±0.155 mm,对照组0.887±0.152 mm(P=0.99)。
  • 5年时IMT年变化:普伐他汀组0.021±0.116 mm,对照组0.040±0.118 mm(P=0.010)。
  • 基线特征除NIHSS评分外组间无显著差异(中位数0 vs 1,P=0.019)。

临床怎么用

  • 对非心源性缺血性卒中日本患者,可考虑使用普伐他汀10mg/日以减缓颈动脉IMT进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The effect of statins on progression of carotid intima-media complex thickness (IMT) has been shown exclusively in nonstroke Western patients. This study aimed to determine the effect of low-dose pravastatin on carotid IMT in Japanese patients with noncardioembolic ischemic stroke. METHODS: This is a substudy of the J-STARS trial (Japan Statin Treatment Against Recurrent Stroke), a multicenter, randomized, open-label, parallel-group trial to examine whether pravastatin reduces stroke recurrence. Patients were randomized to receive pravastatin (10 mg daily, usual dose in Japan; pravastatin group) or not to receive any statins (control group). The primary outcome was IMT change of the common carotid artery for a 5-year observation period. IMT change was compared using mixed-effects models for repeated measures. RESULTS: Of 864 patients registered in this substudy, 71 without baseline ultrasonography were excluded, and 388 were randomly assigned to the pravastatin group and 405 to the control group. Baseline characteristics were not significantly different, except National Institutes of Health Stroke Scale scores (median, 0 [interquartile range, 0-2] versus 1 [interquartile range, 0-2]; P=0.019) between the 2 groups. Baseline IMT (mean±SD) was 0.887±0.155 mm in the pravastatin group and 0.887±0.152 mm in the control group (P=0.99). The annual change in the IMT at 5-year visit was significantly reduced in the pravastatin group as compared with that in the control group (0.021±0.116 versus 0.040±0.118 mm; P=0.010). CONCLUSIONS: The usual Japanese dose of pravastatin significantly reduced the progression of carotid IMT at 5 years in patients with noncardioembolic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00361530.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Koga M, Toyoda K, Minematsu K, et al. Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke). Stroke. 2017. PMID: 29191850. doi:10.1161/STROKEAHA.117.018387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。